These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3581420)

  • 1. Changes in serum iron levels following very high-dose cisplatin.
    Pollera CF; Ameglio F; Reina S; Nardi M; Abbolito MR; Parracino C
    Cancer Chemother Pharmacol; 1987; 19(3):257-60. PubMed ID: 3581420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and late hyperferremia during cisplatin chemotherapy.
    Sartori S; Nielsen I; Masotti M; Malacarne P
    J Chemother; 1991 Feb; 3(1):45-50. PubMed ID: 2019863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose and schedule effects of cisplatin on the related acute iron changes.
    Pollera CF; Ameglio F; Nardi M; Marolla P; Carlini P; Frasca AM
    Oncology; 1990; 47(2):133-8. PubMed ID: 2314826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in blood iron levels during cisplatin chemotherapy. Preliminary results].
    Sartori S; Nielsen I; Malacarne P
    Medicina (Firenze); 1990; 10(1):48-9. PubMed ID: 2381283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
    Veldhuis GJ; Willemse PH; Beijnen JH; Boonstra H; Piersma H; van der Graaf WT; de Vries EG
    Br J Cancer; 1997; 75(5):703-9. PubMed ID: 9043028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous stem cell transplantation: evaluation of erythropoietic reconstitution by highly fluorescent reticulocyte counts, erythropoietin, soluble transferrin receptors, ferritin, TIBC and iron dosages.
    Testa U; Rutella S; Martucci R; Scambia G; D'Onofrio G; Pierelli L; Sica S; Benedetti Panici PL; Menichella G; Foti E; Mastroberardino G; Mancuso S; Leone G; Peschle C
    Br J Haematol; 1997 Mar; 96(4):762-75. PubMed ID: 9074420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum iron levels following administration of cisplatinum.
    Kletter G; Parks BR; Bhatnagar A; Iyer RV
    Oncology; 1988; 45(6):421-3. PubMed ID: 3186150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cis-dichlorodiammine platinum (II) in advanced ovarian carcinoma.
    Stewart JF; Tattersall MH; Woods RL; Fox RM
    Med J Aust; 1979 Jun; 1(12):548-50. PubMed ID: 470725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy.
    Malik IA; Khan ZK; Hakimali A; Sabih M; Rehman G
    J Pak Med Assoc; 1998 May; 48(5):127-31. PubMed ID: 9813972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
    Herben VM; Panday VR; Richel DJ; Schellens JH; van der Vange N; Rosing H; Beusenberg FD; Hearn S; Doyle E; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.
    Andreopoulou E; Chen T; Liebes L; Curtin J; Blank S; Wallach R; Hochster H; Muggia F
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):457-63. PubMed ID: 21069334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of serum CA125 following optimal cytoreductive surgery during weekly cisplatin induction therapy for advanced ovarian cancer.
    Hempling RE; Piver MS; Natarajan N; Baker TR; Thompson JM; Hicks ML; Mettlin CJ
    J Surg Oncol; 1993 Sep; 54(1):38-44. PubMed ID: 8377503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer.
    Gershenson DM; Morris M; Burke TW; Levenback C; Kavanagh JJ; Fromm GL; Silva EG; Warner D; Wharton JT
    Gynecol Oncol; 1995 Sep; 58(3):349-55. PubMed ID: 7672700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
    Gordon AN; Stringer CA; Matthews CM; Willis DL; Nemunaitis J
    J Clin Oncol; 1997 May; 15(5):1965-73. PubMed ID: 9164208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
    Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A
    Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
    Deng C; Huang R; Lian L
    Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.